Transected axons fail to regrow across anatomically complete spinal cord injuries (SCI) in adults. Diverse molecules can partially facilitate or attenuate axon growth during development or after injury 1-3 , but efficient reversal of this regrowth failure remains elusive 4 . Here we show that three factors that are essential for axon growth during development but are attenuated or lacking in adults-(i) neuron intrinsic growth capacity 2,5-9 , (ii) growth-supportive substrate 10,11 and (iii) chemoattraction 12,13 -are all individually required and, in combination, are sufficient to stimulate robust axon regrowth across anatomically complete SCI lesions in adult rodents. We reactivated the growth capacity of mature descending propriospinal neurons with osteopontin, insulin-like growth factor 1 and ciliary-derived neurotrophic factor before SCI 14,15 ; induced growth-supportive substrates with fibroblast growth factor 2 and epidermal growth factor; and chemoattracted propriospinal axons with glial-derived neurotrophic factor 16,17 delivered via spatially and temporally controlled release from biomaterial depots 18,19 , placed sequentially after SCI. We show in both mice and rats that providing these three mechanisms in combination, but not individually, stimulated robust propriospinal axon regrowth through astrocyte scar borders and across lesion cores of non-neural tissue that was over 100-fold greater than controls. Stimulated, supported and chemoattracted propriospinal axons regrew a full spinal segment beyond lesion centres, passed well into spared neural tissue, formed terminal-like contacts exhibiting synaptic markers and conveyed a significant return of electrophysiological conduction capacity across lesions. Thus, overcoming the failure of axon regrowth across anatomically complete SCI lesions after maturity required the combined sequential reinstatement of several developmentally essential mechanisms that facilitate axon growth. These findings identify a mechanism-based biological repair strategy for complete SCI lesions that could be suitable to use with rehabilitation models designed to augment the functional recovery of remodelling circuits.
osteopontin, insulin-like growth factor 1 (IGF1) and ciliary-derived neurotrophic factor (CNTF) (AAV-OIC) 14, 15 . To increase axon growthsupportive substrates such as laminin 10, 11, 19, 24 , we delivered fibroblast growth factor 2 (FGF2) 25 and epidermal growth factor (EGF) 26 . To chemoattract 12, 13 propriospinal axons, we delivered glial-derived growth factor (GDNF) because propriospinal neurons express GDNF receptors (GDNFR), increase GDNFR expression after SCI 16 and regrow axons into GDNF-secreting grafts 17 , and because SCI lesions lack GDNF 19 . To provide temporally controlled and spatially targeted delivery of growth factors or function-blocking antibodies, we used biomaterial depots of synthetic hydrogels 18, 19 placed sequentially into SCI lesion centres and into caudal spared neural tissue ( Fig. 1a , Extended Data Fig. 1 ). AAV injected one segment rostral to SCI lesions efficiently targeted propriospinal neurons, including neurons expressing GDNFR (Extended Data Fig. 2a, b ). These manipulations were tested alone and in combinations, first in adult mice and then in adult rats with severe crush SCI causing anatomically complete lesions, across which there is no spontaneous regrowth of descending or ascending axons 19 .
Propriospinal axon regeneration was quantified as tract-tracerlabelled axons that regrew to lesion centres or beyond ( Fig. 1b-d , Extended Data Figs. 2c-e, 3, 4) . Mice with SCI only or SCI plus empty hydrogel depots exhibited few or no axons at lesion centres. Individual interventions, AAV-shPT or AAV-OIC alone, or depots with FGF and EGF alone or GDNF alone, did not significantly increase this number. Combined delivery of all three growth factors, FGF, EGF and GDNF in one or two depots, but without AAVs, led to modest but significantly increased axon regrowth. Combined delivery of AAV-shPT plus FGF, EGF and GDNF did not significantly increase axon numbers compared with FGF, EGF and GDNF alone or with control AAV delivering a nonsense sequence plus FGF, EGF and GDNF. By contrast, combined delivery of AAV-OIC plus FGF, EGF and GDNF synergistically facilitated robust propriospinal axon regrowth. In mice with two sequentially placed depots, this regrowth passed through non-neural lesion cores and their astrocyte scar borders, and penetrated well into spared grey matter ( Figs. 1-3 , Extended Data Figs. 3, 4) . In these mice, total axon regrowth past lesion centres was over 100-fold greater than SCI only or SCI plus empty depots (Fig. 1c ). Regrowing propriospinal axons expressed detectable GDNFR ( Fig. 1e ) and followed irregular paths ( Fig. 1d ) consistent with regrowing, as opposed to spared, axons 27 . Biontinylated dextran amine (BDA) tract-tracer did not label axons of passage, such as serotonin axons (Extended Data Fig. 2d, e ). In all cases, no BDA-labelled axons were present 3 mm past lesion centres, confirming that lesions were complete ( Fig. 1b-d , Extended Data Figs. 3, 4) .
To dissect potential cellular and molecular mechanisms underlying this robust axon regrowth, we first examined axon-substrate interactions ( Fig. 2 , Extended Data Figs. 5, 6) . FGF with EGF significantly Letter reSeArCH increased known axon-supportive substrate molecules 11 , laminin, fibronectin and collagen in SCI lesions ( Fig. 2a , Extended Data Fig. 5a ), whereas potentially inhibitory chondroitin sulfate proteoglycans (CSPG) 28 were not significantly altered (Fig. 2g ). FGF with EGF significantly increased astrocyte proliferation and density (Fig. 2b ), yet despite this increase, stimulated and chemoattracted propriospinal axons regrew robustly through and beyond proximal ( Fig. 2c ) and distal ( Fig. 3a ) astrocyte scar borders, consistent with observations for sensory axons 19 . FGF with EGF also increased stromal cell density in the lesion core ( Fig. 2a, Extended Data Fig. 6b ). Axons transitioned readily from regrowing along astrocytes in proximal scar borders to regrowing along stromal cells in lesion core (Fig. 2c, Extended Data Fig. 6a ), often orientated along stromal cells or blood vessels and circumventing inflammatory cell clusters (Fig. 2c, Extended Data Fig. 6a-c) . Some regrowing axons partially contacted cells expressing Schwann cell markers (Extended Data Fig. 6d ). Thus, appropriately stimulated and hydrogel depot 1 and 2, respectively. b, BDA-labelled axons in composite tiled scans of horizontal sections also stained for astrocytes (anti-GFAP (glial fibrillary acidic protein), left) and cell nuclei (DAPI). Dotted lines demarcate astrocyte proximal (PB) and distal (DB) border around the lesion core (LC). Dashed line demarcates lesion centre. 1D, one depot; 2D, two depots; GM, grey matter. c, Top, schematic of axon intercept. Middle, axon intercepts at specific distances past lesion centres (colour coding and n as in the graph below). Bottom, areas under axon intercept curves. Dots show n mice per group. NS, not significant versus SCI + 1D empty; *P < 0.01 versus SCI + 1D empty, two-way ANOVA with Bonferroni; **P < 0.01 versus all other groups and not significant versus each other, ***P < 0.0001 versus all other groups, one-way ANOVA with Bonferroni. Data are mean ± s.e.m. PrSp, propiospinal. d, Surveys (top) and details (bottom) of BDA-labelled axons. e, Three-dimensional detail of BDAlabelled axon and growth cone expressing GDNFR in the lesion core. 
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attracted axons regrew in contact with multiple cell types. Notably, over 98% of regrowing propriospinal axons in SCI lesions had at least one surface continually in contact with laminin, whereas axon surfaces in mature uninjured tissue rarely contacted laminin ( Fig. 2d, e ). Many regrowing axons also contacted fibronectin or collagen (Extended Data Fig. 5a ). Simultaneous in vivo delivery of anti-CD29, an integrin-function-blocking antibody 19, 24 , significantly prevented most axon regrowth ( Fig. 2f , Extended Data Figs. 3d, 4), demonstrating that regrowth required integrin-dependent axon-substrate interactions with laminin, fibronectin or collagen.
Nevertheless, upregulation of permissive substrate alone was not sufficient to attract activated axon regrowth. AAV-OIC plus depots of only FGF with EGF exhibited no significant regrowth, whereas AAV-OIC plus FGF, EGF and GDNF did ( Fig. 1c , Extended Data Figs. 3d, 4), demonstrating that axon regrowth also required chemoattraction.
Notably, AAV-OIC plus FGF, EGF and GDNF stimulated axons regrew robustly through dense areas of CSPGs, including in direct contact with brevican or CSPG4 (also known as NG2) in both astrocyte scars and non-neural lesion cores. This regrowth occurred along surfaces with high laminin expression ( Fig. 2h , i, Extended Data Fig. 5b , c), consistent with in vitro observations that CSPG inhibition is relative rather than absolute, such that increasing laminin overrides CSPG presence 29 .
To probe more broadly the effects of prolonged FGF and EGF treatment on astrocytes and other cells in SCI lesions, we conducted genome-wide sequencing of astrocyte-specific ribosome-associated RNA and RNA from non-astrocyte cells 19 at two weeks after SCI. At this time point, FGF and EGF treatment continued to significantly regulate many genes. The most significantly regulated gene networks were associated with astrocyte proliferation and development, and with non-astrocyte inflammatory responses (Extended Data Fig. 7a -c).
We next identified mechanisms required to achieve propriospinal axon regrowth beyond lesion cores and distal borders into spared grey matter. In early experiments with one depot of AAV-OIC plus FGF, EGF and GDNF in lesion cores, we noted that propriospinal axons regrew robustly to surround and encircle depots, but did not pass beyond (Extended Data Fig. 4 ). We therefore injected a second depot of GDNF into spared grey matter caudal to injuries at one week after the first depot (Extended Data Fig. 1b ). In mice with two such spatially and temporally separated depots, axons regrew robustly across lesion cores and distal astrocyte borders and routinely reached a full spinal segment past lesion centres ( Fig. 1b-d , Extended Data Fig. 3a -c), demonstrating that chemoattraction is required to draw robust regrowth of mature endogenous axons into spared neural tissue beyond injuries. Notably, the second depot was placed at nine days after SCI, indicating that GDNF efficiently chemoattracted regrowing axons across already formed distal astrocyte scar borders without altering CSPG levels ( Fig. 3a ; Extended Data Fig. 3b ). Starting just beyond lesion borders (Fig. 3b , c), propriospinal axons regrowing in spared grey matter intermingled with NeuN + neurons, and some formed terminal-like swellings that contacted neurons, colocalized with the pre-synaptic marker synaptophysin and were in apposition with the post-synaptic marker homer ( Fig. 3b-d ). Such contacts were found wherever regrowing axons were present in grey matter, up to a full spinal segment (1,500 μm) beyond lesion centres. As expected and discussed below, over-ground locomotion did not improve in these experiments focused on dissecting the mechanisms required to achieve axon regrowth across lesions (Extended Data Fig. 2f ).
We next tested whether our findings could be extended to rats, in which lesion core pathophysiology has been proposed to be more similar to humans. As expected, rats exhibited little or no propriospinal axon regrowth after SCI with empty hydrogel. Axon regrowth was not increased by AAV-OIC alone, and only minimally by FGF, EGF and GDNF alone. By contrast, and consistent with our observations in mice, rats given combined AAV-OIC plus two depots of FGF, EGF and GDNF exhibited robust propriospinal axon regrowth that routinely reached a full spinal segment or more past lesion centres and penetrated well into spared grey matter around the second depot but not further ( Fig. 4a , b, Extended Data Figs. 8, 9) . Total axon regrowth past lesion centres was over 140-fold greater in rats with AAV-OIC plus FGF, EGF and GDNF versus SCI with empty hydrogel (Fig. 4b ). AAV-derived tract-tracer, red fluorescent protein (RFP), was not expressed by axons of passage such as serotonin axons. Moreover, in contrast to the robust regrowth of RFP-labelled propriospinal axons, serotonin axons exhibited no regrowth (Extended Data Fig. 9c ), indicating that our growth factor depots did not simply alter the lesion core environment to broadly enable regrowth of all axon types. Regrowing propriospinal axons that reached spared grey matter intermingled with NeuN + neurons and some axons formed terminal-like swellings that contacted neurons, colocalized with synaptophysin and were in apposition with homer ( Fig. 4c ). As in mice, over-ground locomotion of rats did not improve in these experiments that probed the mechanisms required for axon regrowth but did not provide rehabilitation to elicit use-dependent plasticity (Extended Data Fig. 9d ). Nevertheless, to look for potential basic functionality of regrown propriospinal axons, we measured electrophysiological signals across lesions. Rats with SCI only exhibited essentially no conduction above background levels across lesions, whereas rats with AAV-OIC plus FGF, EGF and GDNF exhibited conduction at about 25% of control levels at 2 mm past lesions, which disappeared by 5 mm past lesions ( Fig. 4d ), indicating that propriospinal Letter reSeArCH axon regrowth was associated with a significant return of conduction capacity that correlated with the distance of regrowth past lesions. Biological repair of anatomically complete SCI will require axon regrowth across lesions with non-neural tissue cores and astrocyte limitans borders to reach spared grey matter and form new circuits 3 . A mechanistic understanding of why spontaneous axon regrowth fails in adults is fundamental to creating beneficial interventions 4 . Our findings, in both mice and rats, strongly support the hypothesis that adult axon regrowth across such lesions fails primarily because of the simultaneous absence or inadequate presence of three types of mechanisms essential for facilitating developmental axon growth: (i) neuron intrinsic growth capacity 2,5-9 , (ii) supportive substrate 10, 11 and (iii) chemoattraction 12, 13 . We show that each of these mechanisms is required, and that in combination-but not individually-they are sufficient to achieve robust axon regrowth across lesions in spite of the presence of putative growth inhibitors. We extend previous observations that providing individual growth-facilitators is not sufficient to achieve meaningful axon regrowth across complete lesions and combinations can improve regrowth 3, 4, 19, 23, 30, 31 . Importantly, our findings identify chemoattraction as critically required for robust axon regrowth, and point towards the need to identify chemoattractants effective for other axon populations desirable to target after SCI. The different response of propriospinal neurons to AAV-shPT and AAV-OIC reflects previous observations of neuron-specific activation requirements 14 and underlines the need to identify growth activators for different neuronal populations and the means to achieve activation at subacute or chronic times after SCI. Although propriospinal axon regrowth was associated with a significant return of electrophysiological conduction across lesions, there was, as expected 4 , no detectable improvement of locomotor function, consistent with accumulating evidence that new circuits formed after complete SCI cannot be expected to acquire function spontaneously, but will require rehabilitation that fosters their integration into functional networks through use-dependent plasticity 4, 20, 21, 32 . Our findings provide proofof-concept evidence that robust and physiologically active descending propriospinal axon regrowth can be achieved across anatomically complete SCI lesions, and identify a mechanism-based biological repair strategy for such lesions that can be tested in conjunction with targeted rehabilitation paradigms 32 designed to augment synapse remodelling and functional recovery of remodelling circuits.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-018-0467-6. All experiments using mice were conducted at UCLA using C57/BL6 female and male mice. RNA sequencing experiments used C57/BL6 mice expressing an mGFAP-RiboTag transgene generated and characterized as described 19 . All mice used were young adults between ten weeks and four months old at the time of spinal cord injury. Mice receiving AAV injections were between six and nine weeks old at the time of AAV injection. All mice were housed in a 12-h light/dark cycle in a specific pathogen-free facility with controlled temperature and humidity and were allowed free access to food and water. Animal care, including manual bladder voiding, was performed at least twice daily or as needed after SCI for the duration of the experiment. All experiments were conducted according to protocols approved by the Animal Research Committee of the Office for Protection of Research Subjects at University of California Los Angeles. Rats. All surgical procedures in rats were done at EPFL. Experiments were conducted on young adult female Lewis rats between two and four months of age (180-220 g body weight) housed three to a cage on a 12-h light/dark cycle with access to food and water ad libitum. Housing, surgery and euthanasia were performed in compliance with the Swiss Veterinary Law guidelines. Animal care, including manual bladder voiding, was performed twice daily after SCI for the duration of the experiment. All procedures and experiments were approved by the Veterinary Office of the canton of Vaud and the Veterinary Office of the canton of Geneva (Switzerland). Surgical procedures for mice. All surgeries on mice were performed at UCLA under general anaesthesia with isoflurane in oxygen-enriched air using an operating microscope (Zeiss), and rodent stereotaxic apparatus (David Kopf). AAV injections were made two weeks before SCI to allow time for molecular expression and were targeted at propriospinal neurons between one and two segments rostral to the planned locations of SCI lesions after laminectomy of a single vertebra. AAV (see below) were injected into two sites (one on each side of the cord, 0.25 μl (AAV2/9 OPN: 1 × 10 13 , IGF: 5 × 10 12 , CNTF: 5 × 10 12 genome copies per ml in sterile saline)) 0.6 mm below the surface at 0.1 μl per minute using glass micropipettes (ground to 50 to 100 μm tips) connected via high-pressure tubing (Kopf) to 10-μl syringes under the control of microinfusion pumps. Severe crush SCIs were made at the level of T10 after laminectomy of a single vertebra by using No. 5 Dumont forceps (Fine Science Tools) without spacers and with a tip width of 0.5 mm to completely compress the entire spinal cord laterally from both sides for 5 s 19,33-35 (Extended Data Fig. 1 ). Hydrogel depots were injected stereotaxically into the centre of SCI lesions 0.6 mm below surface at 0.15 μl per minute using glass micropipettes (ground to 50-to 100-μm tips) connected via highpressure tubing (Kopf) to 10-μl syringes under the control of microinfusion pumps, 2 days after SCI 36 . Tract-tracing of propriospinal neurons was performed by injection of biotinylated dextran amine 10000 (BDA, Sigma) 10% w/v in sterile saline injected 2 × 0.4 μl into the same rostral segments targeted with AAV injections as described above. In animals receiving two hydrogel depots, the second depot was placed 1 mm caudal to the SCI 9 days after SCI. Timelines of all injections are provided in Extended Data Fig. 1 . All mice received analgesic before wound closure and every 12 h for at least 48 h after injury. Animals were randomly assigned numbers and thereafter were evaluated blind to experimental condition. Surgical procedures for rats. All surgeries on rats were performed at EPFL under general anaesthesia with isoflurane in oxygen-enriched air using an operating microscope (Zeiss), and rodent stereotaxic apparatus (David Kopf). AAV injections were made two weeks before SCI to allow time for molecular expression and were targeted at propriospinal neurons one and two segments rostral to planned locations of SCI lesions after laminectomy of a single vertebra. AAV were injected into four sites (two on each side of the cord, 0.25 μl (AAV2/9 OPN: 1 × 10 13 , IGF: 5 × 10 12 , CNTF: 5 × 10 12 genome copies per ml in sterile saline)) 1.1 mm below the surface at 0.2 μl per minute using glass micropipettes connected via high pressure tubing (Kopf) to 10 μl syringes under the control of microinfusion pumps. Severe crush SCI were made at the level of T10 laminectomy of a single vertebra by using No. 2 Dumont Forceps (Fine Science Tools) without spacers and with a tip of 0.5 mm to completely compress the entire spinal cord laterally from both sides for 5 s (Extended Data Fig. 1 ). Hydrogel depots were injected stereotaxically into the centre of SCI lesions 1.1 mm below the surface at 0.2 μl per minute using glass micropipettes connected via high pressure tubing (Kopf) to 10-μl syringes under the control of microinfusion pumps, 2 days after SCI. One week later, a hydrogel depot was placed 2 mm caudal to the SCI. During the same surgery, tract-tracing of propriospinal neurons was performed by injection of AAV2/5 red fluorescent protein (RFP, University of Pennsylvania Vector Core, 2.612 × 10 13 genome copies per ml) injected 4 × 0.25 μl into the same rostral segments targeted with AAV injections as described above. Timelines of all injections are provided in Extended Data Fig. 1 . All rats received analgesia (buprenorphine Temgesic, ESSEX Chemie AG, Switzerland, 0.01-0.05 mg per kg, subcutaneously) and antibiotics (Baytril 2.5%, Bayer Health Care AG, 5-10 mg per kg, subcutaneously) were provided for 3 and 5 days after surgery, respectfully. Animals were randomly assigned numbers and thereafter were evaluated blind to experimental condition. AAVs. Various AAVs were used to deliver either control AAV of a nonsense scrambled sequence for green fluorescent protein (AAV2/1-scrambled: 5 × 10 12 genome copies per ml) or PTEN knockdown (AAV2/1-shPTEN: 5 × 10 12 genome copies per ml) 23 ; or to express the growth factors osteopontin (OPN), IGF1 and CNTF (AAV2/9 OPN: 1 × 10 13 genome copies per ml; AAV2/9 IGF-1: 5 × 10 12 genome copies per ml; AAV2/9 CNTF: 5 × 10 12 genome copies per ml) 14, 15 ; or to express green fluorescent protein (GFP) as a reporter protein (AAV2/9 GFP: 2 × 10 13 genome copies per ml) or red fluorescent protein (RFP) as an axonal tract-tracer (AAV2/5-RFP: 2.612 × 10 13 genome copies per ml) (University of Pennsylvania Vector Core).
Hydrogel depots with growth factors and function-blocking antibodies.
Biomaterial depots were prepared using well-characterized diblock copolypeptide hydrogels that are CNS biocompatible, biodegrade over several weeks in vivo and provide prolonged delivery of bioactive growth factors in CNS tissue for two or more weeks after injection 18, 19, 37, 38 . Diblock copolypeptide hydrogel K 180 L 20 was fabricated, conjugated with blue fluorescent dye (AMCA-X) and loaded with growth factor and antibody cargoes as described [36] [37] [38] . Cargo molecules were as follows. Human recombinant FGF2, EGF and GDNF were purchased from PeproTech: (i) human FGF2 (FGF-basic) (154 amino acids) Cat#100-18B-100UG, Lot#091608 C0617; (ii) human EGF Cat#AF-100-15-100UG, Lot#0816AFC05 B2317; (iii) human GDNF Cat#405-10-100UG, Lot#0606B64 A2517. Integrin-functionblocking hamster anti-rat CD29 monoclonal antibody was purchased from BD Bioscience as a custom order at 10.3 mg/ml (product #624084; lot#7165896). Freeze-dried K 180 L 20 powder was reconstituted to 3.0% or 3.5% w/v in sterile PBS without cargo or with combinations of FGF2 (1.0 μg/μl), EGF (1.0 μg/μl), GDNF (1.0 μg/μl) and anti-CD29 (5 μg/μl). Diblock copolypeptide hydrogel formulations were prepared to have G′ (storage modulus measured at 10 rad/s and 10% strain) between 75 and 100 Pa, somewhat below that of mouse brain at 200 Pa 37, 38 . Hindlimb locomotor evaluation. At 2, 7, 14 and 28 days after SCI, hindlimb movements were scored using a simple six-point scale in which 0 is no movement and 5 is normal walking 34 . Animal inclusion and exclusion criteria. Two days after SCI, all mice or rats were evaluated in open field and all animals exhibiting any hindlimb movements were not studied further. Rodents that passed this inclusion criterion were randomized into experimental groups for further treatments and were thereafter evaluated blind to their experimental condition. Histology and immunohistochemistry. After terminal anaesthesia by barbiturate overdose mice or rats were perfused transcardially with 4% paraformaldehyde and spinal cords processed for immunofluorescence as described 19, [33] [34] [35] . Primary antibodies were: rabbit anti-GFAP (1:2,000; Dako); rat anti-GFAP (1:1,000, Thermofisher); chicken anti-GFAP (1:1,000, Novus Biologicals); rabbit anti NeuN (1:1,000, Abcam); rabbit anti-GDNFR-a (GDNF-receptor alpha) (1:1,000, Abcam); sheep anti-BrdU (1:300, Maine Biotechnology Services); rabbit anti-HSV-TK (1:1,000 35, 39 ,); goat anti-CD13 (1:1,000, R&D systems); rabbit anti-laminin 1 (1:100, Sigma); rabbit anti-fibronectin (1:500, Millipore); rabbit anti-collagen 1a1 (1:300, Novus Biologicals); mouse anti-NeuN (1:2,000, Millipore); mouse anti-CSPG 40 (1:100, Sigma); rabbit anti-brevican (BCAN) (1:300, Novus Biologicals); guinea pig anti-NG2 (CSPG4) (E. G. Hughes and D. W. Bergles 41 ); rat anti-PECAM-1 (1:200, BD Biosciences); guinea pig anti-homer1 (1:600, Synaptic Systems GmbH); rabbit anti-synaptophysin (1:600, Dako); rabbit anti-RFP (1:1,000, Rockland); chicken anti-RFP (1:500, Novus Biologicals); goat anti-GFP (1:1,000, Novus Biologicals). Fluorescence secondary antibodies were conjugated to: Alexa 488 (green) or Alexa 405 (blue) (Molecular Probes), or to Cy3 (550, red) or Cy5 (649, far red) all from (Jackson Immunoresearch Laboratories). BDA tract-tracing was visualized with streptavidin-horse radish peroxidase (HRP) plus TSB Fluorescein geen or Tyr-Cy3 (Perkin Elmer). Nuclear stain: 4′,6′-diamidino-2-phenylindole dihydrochloride (DAPI; 2 ng/ml; Molecular Probes). Sections were coverslipped using ProLong Gold anti-fade reagent (InVitrogen). Sections were examined and photographed using deconvolution fluorescence microscopy and scanning confocal laser microscopy (Zeiss). Tiled scans of individual whole sections were prepared using a 20× objective and the scanning function of a Leica Aperio Versa 200 Microscope (Leica) available in the UCLA Translational Pathology Core Laboratory. Composite survey images were prepared from tiled scans of multiple sections from the same animals oriented and overlaid using Imaris software (9.1.2 64 Bit, Bitplane, Oxford Instruments). Axon quantification. Axons labelled by tract tracing using BDA or RFP were quantified using image analysis software (NeuroLucida, 9.14.5 32 Bit, MicroBrightField) operating a computer-driven microscope regulated in the x, y and z axes (Zeiss) by observers blind to experimental conditions. Using NeuroLucida, lines were drawn across horizontal spinal cord sections at SCI lesion centres and at regular distances beyond (Fig. 1c, Extended Data Fig. 3a, b ) and the number of axons intercepting lines was counted by observers blind to experimental conditions. Multiple sections Letter reSeArCH through the middle of the cord, in which propriospinal axons were densest, were counted per mouse or rat and expressed as total intercepts per location per animal.
To determine the efficacy of axon transection after SCI, we examined labelling 3 mm distal to SCI lesion centres in mice and 5 mm distal to lesion centres in rats, with the intention of eliminating animals that had labelled axons at this location on the grounds that these mice may have had incomplete lesions. However, essentially all mice or rats that had met the strict behavioural inclusion criterion of no hindlimb movements 2 days after severe crush SCI exhibited no detectable axons 3 mm or 5 mm, respectively, distal to SCI lesions, regardless of treatment group. Quantification of immunohistochemically stained areas. Sections stained for laminin 1, fibronectin, collagen 1a1 or CSPG were scanned using constant exposure settings. Single channel immunofluorescence images were converted to black and white and thresholded ( Fig. 2a ) and the amount of stained area was measured in different tissue compartments using NIH ImageJ (v.1.51) software 19 . Quantification of astrocyte proliferation and density. To quantify astrocyte proliferation and the number of astrocytes in the immediate scar border previously defined as zone 1 35 , we used a well-characterized transgenic mouse line that expresses thymidine kinase in astrocyte cell bodies, thereby facilitating quantification of cell number and co-localization with other markers 35 . To quantify the proportion of newly proliferated astroglia in the scar boarder, we injected daily single doses of the cell division marker, bromodeoxyuridine (BrdU, Sigma), 100 mg/kg/day dissolved in saline plus 0.007 N NaOH on days 2-7 after SCI. Newly proliferated astrocytes were quantified by determining the percentage of astrocytes stained for both GFAP, thymidine kinase and BrdU in zone 1 35 . Total astrocyte numbers in the immediate scar border (zone 1) 35 were determined by counting the number of cells per defined tissue volume. Cell counts were performed using stereological image analysis software (StereoInvestigator, 9.14.5 32 Bit, and NeuroLucida, 9.14.5 32 Bit, MicroBrightField) operating a computer-driven microscope regulated in the x, y and z axes (Zeiss). Dot blot. For the dot blot immunoassay of laminin 1, fibronectin, collagen 1 or CSPG, spinal cord tissue blocks were lysed and homogenized in standard RIPA (radio-immuno-precipitation-assay) buffer. LDS (lithium dodecyl sulfate) buffer (Life Technologies) was added to the post-mitochondrial supernatant and 2 μl containing 2 μg/μl protein was spotted onto a nitrocellulose membrane (Life Technologies), set to dry and incubated overnight with primary antibodies: rabbit anti-laminin 1 (1:4,000, Sigma); rabbit anti-fibronectin (1:7,000, Millipore); rabbit anti-collagen 1a1 (1:7,000, Novus Biologicals); mouse anti-chondroitin sulfate antibody (CS-56, 1:3,000, Sigma Aldrich), an IgM-monoclonal antibody that detects glyco-moieties of all CSPGs 40 . Immunoreactivity was detected on X-ray film with HRP-conjugated secondary antibody (1:5,000) and chemiluminescent substrate (Thermo Fisher). Densitometry measurements of immunoreactivity were obtained using ImageJ software (NIH) and normalized to total protein (Ponceau S) density 42 . Raw images of dot blots are provided as Supplementary Fig. 1 .
Isolation and sequencing of RNA from astrocytes and non-astrocyte cells.
Using mice expressing an mGFAP-RiboTag transgene, RNA was evaluated as previously described 19 from uninjured mice, and mice two weeks after SCI after treatment with hydrogel depots that either contained no cargo (empty depots) or delivered FGF + EGF (Extended Data Fig. 1a ). In brief, spinal cords were rapidly dissected out of the spinal canal and the central 3 mm of the lower thoracic lesion including the lesion core and 1 mm rostral and caudal were rapidly removed and snap-frozen in liquid nitrogen. Haemagglutinin immunoprecipitation of astrocyte ribosomes and ribosome-associate mRNA was carried out as described 43 . The non-precipitated flow through from each sample was collected for analysis of non-astrocyte total RNA. Haemagglutinin and flow-through samples underwent on-column DNA digestion using the RNase-Free DNase Set (Qiagen) and RNA purified with the RNeasy Plus Micro kit (Qiagen). Integrity of the eluted RNA was analysed using a 2100 Bioanalyzer (Agilent) with the RNA Pico chip, average RNA integrity number (RIN) = 7.9 ± 1.4. RNA concentration determined using the RiboGreen RNA Assay kit (Life Technologies). cDNA was generated from 5 ng of immunoprecipitate or flow-through RNA using the Nugen Ovation 2 RNA-Seq Sytstem V2 kit (Nugen). One microgram of cDNA was fragmented using the Covaris M220. Paired-end libraries for multiplex sequencing were generated from 300 ng of fragmented cDNA using the Apollo 324 automated library preparation system (Wafergen Biosystems), enriched over ten cycles of PCR and purified with Agencourt AMPure XP beads (Beckman Coulter). All samples were analysed by an Illumina NextSeq 500 Sequencer (Illumina) using 75-bp pair-end sequencing. The number of reads obtained are between 38.0 to 71.0 million (average 52.1 million). Sequences were aligned to mouse mm10 genome using STAR aligner (v.2.4.0j). Uniquely aligned reads were between 57.1 to 87.0% (average 73.9%). Read counts were determined using HT-seq (v.0.6.0). Differential expression analysis was conducted using Bioconductor EdgeR package (v.3.20.1) after removal of low count genes (five counts for at least two samples). Three samples from astrocyte samples were excluded owing to low RIN values (<5.7), no samples were excluded for non-astrocyte samples.
Rat electrophysiology. Terminal electrophysiological assessments were carried out as previously described 44 four weeks after SCI. In brief, animals were anaesthetized with urethane (1.5 g/kg; intraperitoneally) and core body temperature was maintained at 37 °C using a self-regulating heated pad connected to a rectal probe. Depth of anaesthesia was continually monitored by assessing withdrawal reflexes and respiratory rate. After laminectomy to expose the injury site and 7 mm rostral and caudal to the lesion site by removal of one vertebra on either side of the injury, the dura was removed, and the exposed spinal cord was covered with warm mineral oil to prevent drying. For stimulation, a tungsten bipolar concentric electrode was positioned intraspinally at the rostral-most point of the laminectomy. A silver ball electrode was used to record any evoked activity from the surface of the exposed spinal cord at various locations (above, 2 mm below, and 5 mm below the lesion). Stimulation was delivered in 200 μs square wave pulses at the maximum amplitude possible before large motor responses were evoked (typically between 600 μA and 800 μA) and at a frequency of 0.75 Hz using a STG 4004 stimulus generator (Multi Channel Systems). Evoked activity was amplified and recorded using an A-M systems differential amplifier, PowerLab and LabChart Pro acquisition and analysis system (AD Instruments). For analysis, 30 traces from each recording site were averaged and the peak to peak amplitude of the evoked potential was quantified. Statistics, power calculations, group sizes and reproducibility. Statistical evaluations of repeated measures were conducted by one-way ANOVA with post hoc independent pair-wise analysis as per Bonferroni, or by Student's t-test (Prism, 7.0c, GraphPad). For one-way ANOVA statistical evaluations, F values are also reported in the online Source Data files in the format F(degree of freedom 1, degree of freedom 2) = X. The degrees of freedom are computed as degree of freedom 1 = k − 1, in which k is the number of compared treatments, and degree of freedom 2 = n − k in which n is the total number of samples across the treatment groups. For Student's two-tailed t-test (Prism, 7.0c, GraphPad), t value and degrees of freedom are reported in the format t(degree of freedom) = X. Power calculations were performed using G*Power Software v.3.1.9.2 45 . For quantification of histologically derived neuroanatomical outcomes such as numbers of axons or percentage of area stained, group sizes were used that were calculated to provide at least 80% power when using the following parameters: probability of type I error (α) = 0.05, a conservative effect size of 0.25, 3-10 treatment groups with multiple measurements obtained per replicate. All graphs show mean ± s.e.m. as well as individual values as dot plots. All bar graphs are overlaid with dot plots in which each dot represents the value for one animal to show the distribution of data and the number (n) of animals per group. Files of all individual values are provided as Source Data. The main experiments testing propriospinal axon regrowth across SCI lesions in animals treated with SCI + AAV-OIC + 2D + FGF + EGF + GDNF and the main control groups (SCI + 1D empty, SCI + AAV-OIC + 1D empty, SCI + 2D + FGF + EGF + GDNF) were repeated independently three times in different groups of mice and three times in different groups of rats with similar results. Other experiments testing propriospinal axon regrowth across SCI lesions in animals in all other groups were repeated independently at least twice in different groups of mice with similar results. For all photomicrographs of histological tissue, staining experiments were repeated independently with tissue from at least four, and in most cases six, different animals with similar results. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. Files of Source Data of individual values for all quantitative figures are provided with the paper. Raw images of dot blots are provided as Supplementary Fig. 1 . RNA-seq data are available at the NCBI Gene Expression Omnibus under accession number GSE111529. Other data that support the findings of this study are available from the corresponding authors upon reasonable request.
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Extended Data Fig. 1 | Experimental models and timelines. Mice or rats received different combinations of procedures including adeno-associated virus (AAV) injections, complete crush SCI, injections of one or two depots of hydrogel containing different molecular cargoes and injections of biotinylated dextran amine (BDA) for axonal tract-tracing. AAV injections were made two weeks before SCI to allow time for molecular expression and were targeted at propriospinal neurons (PrSp) between one and two segments rostral to planned locations of SCI lesions. AAVs were used to deliver either potential axon-growth reactivating molecules, GFP to identify targeted neurons or RFP as an axonal tract-tracer. Complete crush SCI lesions were placed at the level of spinal segment T10. Two days after SCI, all animals were behaviourally evaluated for completeness of SCI and only animals with functionally complete SCI were included in subsequent experimental steps. Additional animals with complete SCI were evaluated without hydrogel injections (SCI only). a, Schematic and timeline of one-depot experiments. Two days after complete crush SCI, animals received hydrogel injections targeted to the centre of the non-neural lesion core. These depots (D 1 ) contained different molecular cargos as listed in the schematic. Depots without cargo were referred to as 'empty' . b, Schematic and timeline of two-depot experiments. Two days after complete crush SCI, animals received a D 1 hydrogel injection into the centre of the non-neural lesion core to deliver the growth factors FGF + EGF + GDNF. Nine days after SCI, the animals received a second hydrogel injection (D 2 ) targeted to spared neural tissue 1 to 2 mm caudal to the lesion centre to deliver GDNF to sequentially chemoattract propriospinal axons that had regrown into the lesion core. BDA injections for axonal tract-tracing were targeted at propriospinal neurons between one and two segments rostral to SCI lesions and were placed at the time of injecting either D 1 (a) or D 2 (b). Tissue was collected for evaluation at either two or four weeks after SCI. Electrophysiological evaluations were conducted at four weeks after SCI. For abbreviations, see Extended Data Table 1 .
Extended Data Fig. 3 | Procedures for quantification of BDA-labelled propriospinal axons after SCI. a, Schematics show demarcation of SCI lesion centre (Cn) and evenly spaced lines beyond the lesion centre placed by image analysis software (Neurolucida, MicroBrightField) for quantification of axon intercepts in horizontal tissue sections of mice with SCI and one (D 1 ) or two (D 1 + D 2 ) hydrogel depots. b, Multi-fluorescent, survey images show BDA-labelled axons and GFAP-labelled astrocytes that demarcate astrocyte scar proximal borders and distal borders around the non-neural lesion core after SCI. The hydrogel of the empty depot (left) was tagged with a blue fluorescent label for visualization. Note the essential absence of axons passing the astrocyte scar (AS) proximal border to reach the lesion centre (Cn) or beyond in the mouse with SCI plus empty depot (left), in contrast to the large number of axons that regrew through the lesion core and passed beyond the distal astrocyte scar border into spared grey matter in the mouse with full treatment of stimulatory AAV plus growth factors (right). GFAP staining shows that the SCI lesions are anatomically complete across the entire width of the spinal cord in both cases. Note that the second depot was placed at nine days after SCI, by which time the distal astrocyte scar border was essentially formed 35 . Note also that astrocytes do not migrate into the depots, potentially giving the mistaken impression of cavity formation when looking only at the GFAP channel alone. Nevertheless, examination of other fluorescence channels shows that depot sites clearly contain DAPI-stained stromal cells and BDA-positive axons. c, Large area survey images of BDAlabelled axons in composite mosaic scans of horizontal sections. In a control mouse (top) that received SCI plus empty depot, few axons reach the lesion centre, almost none pass beyond and no axons are present at 3 mm. In the treated mouse (middle) that received stimulatory AAV plus growth factors, many axons regrow through the lesion core and reach or pass 1.5 mm beyond the lesion centre, which is the equivalent length of a full thoracic spinal segment in mice 46 . Note also that there are no axons present at 3 mm, demonstrating that the SCI lesion was complete and that axons that are found past the lesion centre represent axon regrowth after SCI in response to the experimental manipulations. In an uninjured mouse (bottom), there are many labelled axons at the distance equivalent to 3 mm beyond the location of SCI in injured mice. d, Numbers of axon intercepts at lesion centres for all experimental groups. Data are mean ± s.e.m., dots in graphs show numbers and distribution of individual mice per group. NS, not significant versus SCI only; #P < 0.01, versus SCI only and not significant versus each other; **P < 0.01; ***P < 0.001, versus all other groups; one-way ANOVA with Bonferroni, F(12, 57) = 22.3. 

